1. GE HealthCare Technologies Inc. (NASDAQ:GEHC)
GE HealthCare Technologies Inc. (NASDAQ: GEHC) earns the No. 1 position as the strongest overall combination of valuation, profitability, financial stability and real-world artificial intelligence adoption.
The company operates across medical imaging, ultrasound, patient monitoring and pharmaceutical diagnostics. Its equipment is already installed in hospitals and clinics around the world, creating a direct distribution channel for new AI-enabled healthcare products.
This installed base is a major advantage. A startup may develop an impressive medical algorithm but struggle to convince hospitals to change their systems. The company can integrate artificial intelligence into equipment and workflows that healthcare professionals already understand and use.
Its AI applications can help improve image quality, automate measurements, prioritize urgent cases and reduce the amount of time clinicians spend performing repetitive tasks. The company has also consistently ranked among the manufacturers with the largest number of FDA-listed AI-enabled medical-device authorizations. This demonstrates that its AI strategy has progressed beyond laboratory research and into regulated clinical products.
Second-quarter 2026 revenue increased 5.7%, while organic revenue grew 3.5%. Organic orders climbed a record 11.1%, producing a book-to-bill ratio of 1.15. Backlog reached $23.9 billion, providing substantial visibility into future demand. Net income margin was 10.6%, while diluted EPS increased 16.5% to $1.24. The official second-quarter report provides the complete financial results and guidance.
At approximately $68.86 per share, the stock traded at around 15.8 times trailing earnings. That is a considerably more reasonable valuation than those of many medical-device and artificial intelligence companies. Investors receive exposure to AI-powered diagnostics without depending on a single experimental treatment or an uncertain biotechnology financing cycle.
The tradeoff is that a large and established company is less likely to produce the sudden 10-fold gains possible in a successful micro-cap biotechnology stock. Nevertheless, it also carries a much lower probability of complete failure.
For investors searching for cheap AI medicine stocks to buy now, this represents the most credible risk-adjusted opportunity. Its growing order book, global customer base, profitable operations and leadership in AI-enabled medical technology give it several paths to create long-term shareholder value.
YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
